Clinical Trials Directory

Trials / Completed

CompletedNCT04422314

ImmuneSense Lyme Study

Status
Completed
Phase
Study type
Observational
Enrollment
893 (actual)
Sponsor
Adaptive Biotechnologies · Industry
Sex
All
Age
7 Years
Healthy volunteers

Summary

ImmuneSense Lyme is a study, which is designed to better understand the immune response to Lyme disease. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. Data collected from this study may accelerate the development of better diagnostics for Lyme disease and improve outcomes for many.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTT-Detect LymeT-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.

Timeline

Start date
2020-07-09
Primary completion
2021-10-29
Completion
2021-10-30
First posted
2020-06-09
Last updated
2022-04-15

Locations

34 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04422314. Inclusion in this directory is not an endorsement.

ImmuneSense Lyme Study (NCT04422314) · Clinical Trials Directory